Left Hemithyroidectomy in Combined Thyroid Cancer with Previous Right Lobe Tumour Surgery: a Clinical Case
https://doi.org/10.24060/2076-3093-2021-11-1-46-50
Abstract
Background. Combined thyroid cancer is extremely rare. There is no unified approach currently to the choice of treatment and extent of surgery in combined cancer.
Aim. A clinical case description of left hemithyroidectomy for follicular papillary cancer in a patient previously operated for follicular right lobe cancer with right recurrent laryngeal nerve injury.
Materials and methods. Patient N., 48 yo, had a routine surgical admission in December 2019 with nodular goiter in left thyroid lobe. Suspicio c-r of left thyroid lobe. Condition after right hemithyroidectomy in 2002, postoperative paresis of right recurrent laryngeal nerve.
Results. The patient had a routine surgery upon further examination. Morbid histology corresponded to follicular papillary cancer of left thyroid lobe.
Discussion. Combined thyroid cancers are relatively poorly documented, stimulating further case studies. The chosen extent of surgery and iatrogenic injury of right recurrent laryngeal nerve in history are also distinctive of this clinical case.
Conclusion. A non-standard extent of surgery is described in a clinical case of combined thyroid cancer complicated by postoperative paresis of right recurrent laryngeal nerve in history.
About the Authors
S. P. Muzhikov
“Shale Sante” LLC
Russian Federation
Russian Federation
Stanislav P. Muzhikov — Cand. Sci. (Med.), surgeon
Krasnodar
M. Iu. Eremenko
“Shale Sante” LLC
Russian Federation
Russian Federation
Marina Iu. Eremenko — surgeon
Krasnodar
References
1. Beltsevich D.G., Vanushko V.E., Rumiantsev P.O., Melnichenko G.A., Kuznetsov N.S., Abrosimov A.Yu., et al. 2017 Russian clinical practice guidelines for differentiated thyroid cancer diagnosis and treatment. Endocrine Surgery. 2017;11(1):6–27 (In Russ.). DOI: 10.14341/serg201716-27
2. Younis E. Oncogenesis of thyroid cancer. Asian Pac J Cancer Prev. 2017;18(5):1191–9. DOI: 10.22034/APJCP.2017.18.5.1191
3. Gandolfi G., Ragazzi M., Frasoldati A., Piana S., Ciarrocchi A., Sancisi V. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. Eur J Endocrinol. 2015;172(4):403–13. DOI: 10.1530/EJE-14-0837
4. Liu T., Yuan X., Xu D. Cancer-specific telomerase reverse transcriptase (TERT) promoter mutations: biological and clinical implications. Genes. 2016;7(7):38. DOI: 10.3390/genes7070038
5. Liu R., Xing M. TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 2016;23(3):R143–55. DOI: 10.1530/ERC-15-0533
6. Jin A., Xu J., Wang Y. The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer. Medicine (Baltimore). 2018;97(29):e11548. DOI: 10.1097/MD.0000000000011548
7. Karunamurthy A., Panebianco F., J Hsiao S., Vorhauer J., Nikiforova M.N., Chiosea S., et al. Prevalence and phenotypic correlations of EIF1AX mutations in thyroid nodules. Endocr Relat Cancer. 2016;23(4):295–301. DOI: 10.1530/ERC-16-0043
8. Abdullah M.I., Junit S.M., Ng K.L., Jayapalan J.J., Karikalan B., Hashim O.H. Papillary thyroid cancer: genetic alterations and molecular biomarker investigations. Int J Med Sci. 2019;16(3):450–60. DOI: 10.7150/ijms.29935
9. Cibas E.S., Ali S.Z. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid. 2017;27(11):1341–6. DOI: 10.1089/thy.2017.0500
10. Haugen B.R., Alexander E.K., Bible K.C., Doherty G.M., Mandel S.J., Nikiforov Y.E., et al. 2015 American thyroid association management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. DOI: 10.1089/thy.2015.0020
11. Wei X., Li Y., Zhang S., Gao M. Meta-analysis of thyroid imaging reporting and data system in the ultrasonographic diagnosis of 10,437 thyroid nodules. Head Neck. 2016;38(2):309–15. DOI: 10.1002/hed.23878
12. Rossi M., Buratto M., Tagliati F., Rossi R., Lupo S., Trasforini G., et al. Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer. Thyroid. 2015;25(2):221–8. DOI: 10.1089/thy.2014.0338
13. Ross D.S., Burch H.B., Cooper D.S., Greenlee M.C., Laurberg P., Maia A.L., et al. 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–421. DOI: 10.1089/thy.2016.0229
14. Perros P., Watkinson J., Williams G.R. British Thyroid Association guidelines for the management of thyroid cancer. Clin. Endocrinol. 2014;81:1–122. DOI: 10.1111/cen.12515
15. Ikeda Y., Takami H., Sasaki Y., Takayama J., Kan S., Niimi M. Minimally invasive video-assisted thyroidectomy and lymphadenectomy for micropapillary carcinoma of the thyroid. J Surg Oncol. 2002;80(4):218–21. DOI: 10.1002/jso.10128
Review
For citations:
Muzhikov S.P., Eremenko M.I. Left Hemithyroidectomy in Combined Thyroid Cancer with Previous Right Lobe Tumour Surgery: a Clinical Case. Creative surgery and oncology. 2021;11(1):46-50. (In Russ.) https://doi.org/10.24060/2076-3093-2021-11-1-46-50
Views:
1668
Email this article 